Putnam Investments’s Aerie Pharmaceuticals AERI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-62,113
Closed -$1.84M 953
2019
Q2
$1.84M Buy
62,113
+8,322
+15% +$321K ﹤0.01% 731
2019
Q1
$2.56M Buy
53,791
+8,043
+18% +$354K 0.01% 661
2018
Q4
$1.65M Hold
45,748
﹤0.01% 670
2018
Q3
$2.82M Buy
45,748
+29,231
+177% +$1.88M 0.01% 707
2018
Q2
$1.11M Buy
+16,517
New +$924K ﹤0.01% 833
2017
Q2
Sell
-5,038
Closed -$229K 1342
2017
Q1
$229K Sell
5,038
-210,282
-98% -$9.38M ﹤0.01% 1205
2016
Q4
$8.15M Sell
215,320
-110,069
-34% -$4.16M 0.02% 426
2016
Q3
$12.3M Buy
325,389
+5,489
+2% +$121K 0.03% 350
2016
Q2
$5.63M Hold
319,900
0.01% 576
2016
Q1
$3.89M Hold
319,900
0.01% 744
2015
Q4
$7.79M Hold
319,900
0.02% 532
2015
Q3
$5.67M Hold
319,900
0.01% 624
2015
Q2
$5.65M Hold
319,900
0.01% 678
2015
Q1
$10M Hold
319,900
0.02% 497
2014
Q4
$9.34M Hold
319,900
0.02% 522
2014
Q3
$6.62M Hold
319,900
0.01% 647
2014
Q2
$7.92M Sell
319,900
-1,100
-0.3% -$19.1K 0.02% 573
2014
Q1
$6.8M Buy
321,000
+900
+0.3% +$18.2K 0.02% 630
2013
Q4
$5.75M Buy
+320,100
New +$4.17M 0.01% 683

Other funds holding AERI

Putnam Investments's AERI Position: Q3 2019 in Review

Putnam Investments sold out of Aerie Pharmaceuticals (AERI) in Q3 2019, closing a stake of 62,113 shares — an estimated $1.84M sold.

Putnam Investments first reported a position in AERI in Q4 2013 and held it in 19 quarters. The position peaked at $12.3M in Q3 2016. 167 funds tracked by Wall St. Rank hold AERI as of Q3 2019.

  • Putnam Investments reported no remaining Aerie Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Putnam Investments sold 62,113 Aerie Pharmaceuticals shares in Q3 2019, an estimated $1.84M.
  • Putnam Investments first reported a position in Aerie Pharmaceuticals in Q4 2013 and held it in 19 quarters.
  • Putnam Investments's Aerie Pharmaceuticals position peaked at $12.3M in Q3 2016.
  • 167 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2019.

Based on Putnam Investments's 13F filing for Q3 2019, filed 14 Nov 2019.